Cargando…
Human inhalable antibody fragments neutralizing SARS-CoV-2 variants for COVID-19 therapy
As of December 2021, coronavirus disease 2019 (COVID-19), caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), remains a global emergency, and novel therapeutics are urgently needed. Here we describe human single-chain variable fragment (scFv) antibodies (76clAbs) that block a...
Autores principales: | Minenkova, Olga, Santapaola, Daniela, Milazzo, Ferdinando Maria, Anastasi, Anna Maria, Battistuzzi, Gianfranco, Chiapparino, Caterina, Rosi, Antonio, Gritti, Giuseppe, Borleri, Gianmaria, Rambaldi, Alessandro, Dental, Clélia, Viollet, Cécile, Pagano, Bruno, Salvini, Laura, Marra, Emanuele, Luberto, Laura, Rossi, Antonio, Riccio, Anna, Merlo Pich, Emilio, Santoro, Maria Gabriella, De Santis, Rita |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society of Gene & Cell Therapy
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8837488/ https://www.ncbi.nlm.nih.gov/pubmed/35167974 http://dx.doi.org/10.1016/j.ymthe.2022.02.013 |
Ejemplares similares
-
Spike mutation resilient scFv76 antibody counteracts SARS-CoV-2 lung damage upon aerosol delivery
por: Milazzo, Ferdinando M., et al.
Publicado: (2023) -
ErbB2 Targeted Epigenetic Modulation: Anti-tumor Efficacy of the ADC Trastuzumab-HDACi ST8176AA1
por: Milazzo, Ferdinando Maria, et al.
Publicado: (2020) -
AvidinOX-anchored biotinylated trastuzumab and pertuzumab induce down-modulation of ErbB2 and tumor cell death at concentrations order of magnitude lower than not-anchored antibodies
por: Milazzo, Ferdinando Maria, et al.
Publicado: (2017) -
Efficacy of aerosol therapy of lung cancer correlates with EGFR paralysis induced by AvidinOX-anchored biotinylated Cetuximab
por: Santis, Rita De, et al.
Publicado: (2014) -
Intra-tumor AvidinOX allows efficacy of low dose systemic biotinylated Cetuximab in a model of head and neck cancer
por: Vesci, Loredana, et al.
Publicado: (2015)